Remove 2021 Remove Clinical Development Remove Therapies
article thumbnail

Actithera draws new investors to radiopharma drug pitch

BioPharma Drive: Drug Pricing

Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. subsidiary of Merck KGaA, is the founder of radioligand therapy developer Actithera.

Drugs 155
article thumbnail

Navigating Clinical Development Challenges to Advance Idiopathic Pulmonary Fibrosis Treatments

PPD

The road ahead for idiopathic pulmonary fibrosis treatments The landscape of idiopathic pulmonary fibrosis treatment development is poised to evolve significantly. With the expiration of pirfenidone’s patent exclusivity in 2021, sponsors have renewed their focus on developing new therapies. Ready to connect?

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

From siloed data to breakthroughs: multimodal AI in drug discovery

Drug Target Review

Drug development faces significant challenges: long timelines, high costs , complex processes and low probabilities of success (PoS), exacerbated by the shift towards more complex molecules, biologics and cell and gene therapies, hindering patient access to vital treatments. Lifescienceleader.com.

Drugs 64
article thumbnail

Best-in-Class Solutions Accelerate Development of GLP-1 Therapeutics

PPD

This expansion is creating opportunities for clinical trials related to a range of new therapy areas and their subpopulations. Engaging a representative patient population As with most clinical trials, GLP-1 studies are typically challenged to engage a pool of participants that reflects the diversity of the overall patient population.

article thumbnail

CroíValve Secures Horizon Europe EIC Accelerator Funding

The Pharma Data

This support will accelerate the clinical development of the company’s pioneering DUO™ System—a minimally invasive transcatheter device designed to treat severe cases of tricuspid regurgitation. These attributes are expected to make the therapy more accessible in routine clinical practice. The funding comprises a €2.5

article thumbnail

Regulatory Trends in Cell and Gene Therapies

Advarra

The field of cell and gene therapies (CGT) is constantly evolving, and there has been significant progress in this area of research. However, despite the promise of these therapies, the regulations governing them lag the science, which in turn hinders the clinical translation of these novel medicines.

article thumbnail

Cancer immunotherapy: GDF-15’s role in Anti-PD-1 resistance

Drug Target Review

Neutralising GDF-15 with CatalYm’s anti-GDF-15 antibody visugromab was shown to reverse its inhibitory effects and to re-sensitise tumours to anti-PD-1 treatment, achieving commensurate survival benefit of anti-GDF-15-anti-PD-1 combination therapy in vivo. 2021 Jul 6;120(13):2644-56. Biophysical Journal. Springer TA, Dustin ML.